Active Biotech: RhuDex for rheumatoid arthritis concludes phase 1 clinical trials

By E. Janene Geiss

Philadelphia, March 9 - Active Biotech AB and Avidex announced Thursday that the product candidate RhuDex has successfully completed two phase 1 studies looking at safety, tolerability and pharmacokinetics in normal, healthy volunteers.

Avidex said it will now start a dose-escalating, double blind pilot phase 1/ 2 study in rheumatoid arthritis patients, according to a company news release.

The study is designed to investigate safety, pharmacokinetics and drug interactions in patients and is expected to start recruitment beginning in mid-2006, officials said.

For Active Biotech, the agreement with Avidex entailed an initial payment in 2002 and eligibility for milestone payments totaling up to £5.8 million and royalties on future sales.

Active Biotech received a milestone payment from Avidex when the phase 1 study was initiated in the first half 2005, officials said.

Active Biotech is a Lund, Sweden, biotechnology company focused on research and development of pharmaceuticals to treat autoimmune/inflammatory diseases and cancer.

Avidex is a Milton Park, England, biotechnology company focused on the development of small molecule and protein therapeutics involving T cell receptors, either as drug targets or as the therapeutic molecule.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.